As of April 2024 Adaptimmune Therapeutics has a market cap of $0.27 Billion. This makes Adaptimmune Therapeutics the world's 6628th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $0.27 B | 53.25% |
2023 | $0.18 B | -24.7% |
2022 | $0.23 B | -59.17% |
2021 | $0.58 B | -29.79% |
2020 | $0.83 B | 561.11% |
2019 | $0.12 B | -79.01% |
2018 | $0.60 B | -3.92% |
2017 | $0.62 B | 118.3% |
2016 | $0.28 B | -66.42% |
2015 | $0.85 B |
On Apr 24th, 2024 the market cap of Adaptimmune Therapeutics was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
uniQure QURE | $0.21 B | -20.96% | ๐ณ๐ฑ Netherlands |
Novavax NVAX | $0.58 B | 110.43% | ๐บ๐ธ USA |
Exelixis EXEL | $6.98 B | 2,432.44% | ๐บ๐ธ USA |
Enzo Biochem ENZ | $54.29 M | -80.33% | ๐บ๐ธ USA |